Podcast Episodes
Back to Search
Ep. 336 - Cautious Optimism and M&A Momentum
Season 6 Episode 336
There is cautious optimism around continued M&A momentum and the public equities markets as biotech heads into the New Year. On a special edition of …
9 months, 2 weeks ago
Ep. 335 - Neurology's Coming Inflection Point
Season 6 Episode 335
Voyager CEO and former head of R&D at Biogen Al Sandrock is more optimistic than ever about the prospect of bringing clinically meaningful solutions …
9 months, 2 weeks ago
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
Season 6 Episode 334
Richard Pazdur took the top job at FDA’s Center for Drug Evaluation and Research after receiving vows that he would be leading CDER free from politic…
9 months, 3 weeks ago
Ep. 333 - Is This Korea’s Biotech Moment?
Season 6 Episode 333
Today’s South Korean biotechs have a risk-on mentality, a willingness to partner, and strategies focused on globalization. On a special edition of th…
9 months, 3 weeks ago
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
Season 6 Episode 332
With ObesityWeek yielding eye-catching amylin data and a bidding war that ran to $10 billion for Metsera, weight loss companies were center stage in …
9 months, 4 weeks ago
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Season 6 Episode 331
Novo Nordisk’s unsolicited $8.5 billion bid for Metsera has thrown a wrench into Pfizer’s plans to return to the obesity race via its acquisition of …
10 months ago
Ep. 330 - China's Innovation Moment
Season 6 Episode 330
China is setting a new bar for the speed of clinical development and redefining the time it takes an asset to get to the clinic. On a special edition…
10 months, 1 week ago
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
Season 6 Episode 329
Novartis’ biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the…
10 months, 1 week ago
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
Season 6 Episode 328
Next-generation platforms and technologies are getting closer to cracking one of biopharma’s biggest problems: delivering medicines, and mAbs in part…
10 months, 2 weeks ago
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
Season 6 Episode 327
It’s been a tough year for cell and gene therapy — patient deaths, high-profile companies pulling out of the space, and sour investment sentiment. Bu…
10 months, 3 weeks ago